GF
BIOTU

Gabelli Funds’s Biotech Acquisition Company Unit BIOTU Stock Holding History

Gabelli Funds’s Portfolio BIOTU Stock Details BIOTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-24,600
Closed -$247K – 1451
2021
Q3 		$247K Hold
24,600
– – ﹤0.01% 1214
2021
Q2 		$247K Hold
24,600
– – ﹤0.01% 1203
2021
Q1 		$243K Buy
+24,600
New +$253K ﹤0.01% 1196

Other funds holding BIOTU

HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
SMA
Sage Mountain Advisors Atlanta, Georgia $1.43B AUM 16.47% 1-Year Est. Return
COPPSERS
Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return
WCMNY
Westchester Capital Management (New York) Valhalla, New York $2.21B AUM 26.02% 1-Year Est. Return
WC
Wealthspring Capital West Harrison, New York $448M AUM 8.38% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SIA
Schechter Investment Advisors Birmingham, Michigan $1.21B AUM 8.73% 1-Year Est. Return
BCM
BCK Capital Management Stamford, Connecticut $23M AUM 33.03% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return

Gabelli Funds's BIOTU Position: Q4 2021 in Review

Gabelli Funds sold out of Biotech Acquisition Company Unit (BIOTU) in Q4 2021, closing a stake of 24,600 shares — an estimated $247K sold.

Gabelli Funds first reported a position in BIOTU in Q1 2021 and held it in 3 quarters. The position peaked at $247K in Q3 2021. 15 funds tracked by Wall St. Rank hold BIOTU as of Q4 2021.

  • Gabelli Funds reported no remaining Biotech Acquisition Company Unit position as of Q4 2021 after selling out during the quarter.
  • Gabelli Funds sold 24,600 Biotech Acquisition Company Unit shares in Q4 2021, an estimated $247K.
  • Gabelli Funds first reported a position in Biotech Acquisition Company Unit in Q1 2021 and held it in 3 quarters.
  • Gabelli Funds's Biotech Acquisition Company Unit position peaked at $247K in Q3 2021.
  • 15 funds tracked by Wall St. Rank held Biotech Acquisition Company Unit as of Q4 2021.

Based on Gabelli Funds's 13F filing for Q4 2021, filed 11 Feb 2022.